Novartis has announced a new organisational structure, which is expected to result in further (financial) benefits in the medium-to-long term. Importantly, this rejig is targeted to help the group to become more agile in the face of rapidly-evolving market dynamics. Moreover, reiteration of the mid-term ‘sales + margin’ targets are icing on the cake and should calm the nerves of investors, who have been waiting (patiently) for the firm’s share price revival. Overall, our positive stance on the S ....
